ABT 492

Known as: ABT-492, ABT492 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2018
024620032018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The purpose of this study was to compare the mutant prevention concentration (MPC) of ABT-492 to those of levofloxacin… (More)
Is this relevant?
2004
2004
In vitro activities of ABT-492, ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin were… (More)
Is this relevant?
2004
2004
OBJECTIVES The in vitro activity of a new fluoroquinolone, ABT-492, was determined. METHODS MICs were compared with those of… (More)
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2004
2004
OBJECTIVE To compare the kinetics of killing/regrowth of differentially susceptible clinical isolates of Staphylococcus aureus… (More)
Is this relevant?
2004
2004
ABT-492 is a novel quinolone with potent activity against gram-positive, gram-negative, and atypical pathogens, making this… (More)
Is this relevant?
2003
2003
ABT-492 demonstrated potent antibacterial activity against most quinolone-susceptible pathogens. The rank order of potency was… (More)
Is this relevant?
2003
2003
We determined in vitro susceptibilities for ABT-492 and other antimicrobials against Mycoplasma pneumoniae, Mycoplasma fermentans… (More)
  • table 1
  • table 2
Is this relevant?
2003
2003
ABT-492 exhibited excellent in vitro activities against all 326 aerobic and anaerobic antral puncture sinus isolates tested with… (More)
  • table 1
Is this relevant?
2003
2003
A total of 6,991 unique patient isolates of Streptococcus pneumoniae were collected from October 1997 to June 2002 from 25… (More)
Is this relevant?
2003
2003
A total of 7,566 unique patient isolates of Haemophilus influenzae and 2,314 unique patient isolates of Moraxella catarrhalis… (More)
Is this relevant?